These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21907091)

  • 41. Tardive dyskinesia: An update.
    Kulkarni SK; Naidu PS
    Drugs Today (Barc); 2001 Feb; 37(2):97-119. PubMed ID: 12783102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies.
    Jeste DV; Lohr JB; Eastham JH; Rockwell E; Caligiuri MP
    J Psychiatr Res; 1998; 32(3-4):201-14. PubMed ID: 9793874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Tardive dyskinesia: diagnosis, assessment and treatment].
    Frascarelli M; Paolemili M; Gallo M; Parente F; Biondi M
    Riv Psichiatr; 2013; 48(3):187-96. PubMed ID: 23752802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.
    Alblowi MA; Alosaimi FD
    Neurosciences (Riyadh); 2015 Oct; 20(4):376-9. PubMed ID: 26492119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models.
    Creed MC; Nobrega JN
    Curr Med Chem; 2013; 20(3):389-96. PubMed ID: 23157631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment Strategies for Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31880872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The genetics of antipsychotic-related movement disorders].
    Bakker PR; van Os J; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):114-9. PubMed ID: 25669949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tardive Syndrome Is a Mysterious Phenomenon with Different Clinical Manifestations-Review.
    Badarny S; Nassar R; Badarny Y
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects.
    Remington G; Hahn M
    J Psychiatry Neurosci; 2014 Jan; 39(1):E1-2. PubMed ID: 24359929
    [No Abstract]   [Full Text] [Related]  

  • 50. Tardive Dyskinesia: A Historical Perspective.
    Macaluso M; Flynn A; Preskorn SH
    J Psychiatr Pract; 2017 Mar; 23(2):121-129. PubMed ID: 28291037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Restless tongue: Lingual Tardive Dyskinesia - A rare case report.
    Ruparelia P; Pandya U; Gill N; Verma O
    J Oral Biol Craniofac Res; 2022; 12(1):99-101. PubMed ID: 34820254
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-Induced Movement Disorders.
    Pandey S; Pitakpatapee Y; Saengphatrachai W; Chouksey A; Tripathi M; Srivanitchapoom P
    Semin Neurol; 2023 Feb; 43(1):35-47. PubMed ID: 36828011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptics and abnormal movements.
    Lader MH
    Br Med J (Clin Res Ed); 1982 Aug; 285(6340):463-4. PubMed ID: 6125232
    [No Abstract]   [Full Text] [Related]  

  • 54. Monitoring for drug-induced movement disorders.
    Johnson BG
    Nursing; 2017 May; 47(5):56-60. PubMed ID: 28445339
    [No Abstract]   [Full Text] [Related]  

  • 55. The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
    Andreassen OA; Jørgensen HA
    Life Sci; 1995; 57(24):2263-72. PubMed ID: 7475980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperkinetic Rat Model Induced by Optogenetic Parafascicular Nucleus Stimulation.
    Chung M; Park YS
    J Korean Neurosurg Soc; 2023 Mar; 66(2):121-132. PubMed ID: 36239081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.
    Tsermpini EE; Redenšek S; Dolžan V
    Front Pharmacol; 2021; 12():834129. PubMed ID: 35140610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Animal models of tardive dyskinesia.
    Kulkarni SK; Dhir A
    Int Rev Neurobiol; 2011; 98():265-87. PubMed ID: 21907091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
    Grover S; Kumar P; Singh K; Vikram V; Budhiraja RD
    Pharmacol Biochem Behav; 2013 Oct; 111():17-23. PubMed ID: 23948071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.